Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL9 | O00512 | 1/20 | 0.50 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | MGLL | Q99685 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.43 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.43 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL356806 | 0.85 | BCL9 (0.57) | BCL9CTNNB1HTR2AGAAKMT2A | |
| SCHEMBL8915013 | 0.85 | BCL9 (0.50) | BCL9CTNNB1HTR2AGAAKMT2A | |
| SCHEMBL30232724 | 0.82 | BCL9 (0.51) | BCL9CTNNB1HTR2AGAAKMT2A | |
| SCHEMBL29830631 | 0.82 | BCL9 (0.58) | BCL9CTNNB1HTR2AGAAKMT2A | |
| SCHEMBL29654784 | 0.80 | HTR2A (0.52) | BCL9CTNNB1HTR2AGAAKMT2A | |
| SCHEMBL26976971 | 0.80 | MGLL (0.56) | BCL9CTNNB1HTR2AGAAKMT2A | |
| SCHEMBL27108049 | 0.80 | BCL9 (0.56) | BCL9CTNNB1HTR2AGAAKMT2A | |
| SCHEMBL5712385 | 0.80 | BCL9 (0.51) | BCL9CTNNB1HTR2AGAAKMT2A | |
| SCHEMBL26374 | 0.80 | GAA (0.65) | BCL9CTNNB1HTR2AGAAKMT2A | |
| SCHEMBL1059539 | 0.80 | HTR2A (0.60) | BCL9CTNNB1HTR2AGAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120016119-A1 | NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-01-19 | — | — | US | disclosed |
| US-20120016119-A1 | NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-01-19 | — | — | US | disclosed |
| US-20120016119-A1 | NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120016119-A1 | NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND | GPR119, GPR139, HCAR1 | BCL9 1839/4885CTNNB1 2154/4885HTR2A 624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.